Abstract
The essence of the adaptive immune system is self tolerance, which is maintained by various central and peripheral check points. However, the tolerance mechanisms can be broken in autoimmune disease conditions due to genetic predisposition and environmental triggers. As a consequence, a patient’s tissue is attacked by his/her own adaptive immune system. An ideal therapy for autoimmune diseases should include methods to re-establish tolerance to the underpinning autoantigen(s). During the last 15 years our lab has been dedicated to developing a novel B-cell gene therapy approach for antigen-specific tolerance induction. This approach has been successfully applied to at least five different animal models for human autoimmune diseases. In this article, we will discuss many of our successful preclinical studies using the B-cell gene therapy approach to induce tolerance, as well as similar studies from others. Particular focus will be given to the tolerance induction mechanisms that have been revealed from these studies.
Keywords: Tolerance, B cells, gene therapy, immune system, self tolerance, autoimmune disease, B-cell gene therapy, environmental triggers, patient’s tissue, antigen receptors, immature lymphocytes, systemic lupus erythematosis, cancer, immune therapies, hemophilia
Infectious Disorders - Drug Targets
Title:B-Cell Based Gene Therapy for Autoimmune Diseases
Volume: 12 Issue: 3
Author(s): David W. Scott, Ai-Hong Zhang and Yan Su
Affiliation:
Keywords: Tolerance, B cells, gene therapy, immune system, self tolerance, autoimmune disease, B-cell gene therapy, environmental triggers, patient’s tissue, antigen receptors, immature lymphocytes, systemic lupus erythematosis, cancer, immune therapies, hemophilia
Abstract: The essence of the adaptive immune system is self tolerance, which is maintained by various central and peripheral check points. However, the tolerance mechanisms can be broken in autoimmune disease conditions due to genetic predisposition and environmental triggers. As a consequence, a patient’s tissue is attacked by his/her own adaptive immune system. An ideal therapy for autoimmune diseases should include methods to re-establish tolerance to the underpinning autoantigen(s). During the last 15 years our lab has been dedicated to developing a novel B-cell gene therapy approach for antigen-specific tolerance induction. This approach has been successfully applied to at least five different animal models for human autoimmune diseases. In this article, we will discuss many of our successful preclinical studies using the B-cell gene therapy approach to induce tolerance, as well as similar studies from others. Particular focus will be given to the tolerance induction mechanisms that have been revealed from these studies.
Export Options
About this article
Cite this article as:
W. Scott David, Zhang Ai-Hong and Su Yan, B-Cell Based Gene Therapy for Autoimmune Diseases, Infectious Disorders - Drug Targets 2012; 12 (3) . https://dx.doi.org/10.2174/187152612800564383
DOI https://dx.doi.org/10.2174/187152612800564383 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sexual Dimorphism in Autoimmune Disease
Current Molecular Medicine The Unique Inhibitory IgG Receptor--FcγRIIb
Protein & Peptide Letters Recent Advances in Regulatory T Cell Therapy of Autoimmunity, Graft Rejection and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Therapeutic Potential of Glycolipid Ligands for Natural Killer (NK) T Cells in the Suppression of Autoimmune Diseases
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy Small Molecular Inhibitors for the Treatment of Rheumatoid Arthritis: Progress so Far
Mini-Reviews in Medicinal Chemistry Anti-CCP Antibody Detection Facilitates Early Diagnosis and Prognosis of Rheumatoid Arthritis
Current Rheumatology Reviews Modulation of the Immune Response by the Cholera-like Enterotoxins
Current Topics in Medicinal Chemistry Potassium Channel Blockade by the Sea Anemone Toxin ShK for the Treatment of Multiple Sclerosis and Other Autoimmune Diseases
Current Medicinal Chemistry Inhibition of Type 1 Diabetes Development by Vitamin D Receptor Agonists
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents B Cell Depletion with Rituximab in Graves Disease and Associated Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Autoimmune Diseases in Gastroenterology
Current Pharmaceutical Design The Role of STATs in Inflammation and Inflammatory Diseases
Current Pharmaceutical Design Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Current Molecular Medicine B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design Inhibitor at the Gates, Inhibitor in the Chamber: Allosteric and Competitive Inhibitors of the Proteasome as Prospective Drugs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Lipid-Based Nanocarriers for RNA Delivery
Current Pharmaceutical Design Vitamin D Analogs: Mechanism of Action and Therapeutic Applications
Current Medicinal Chemistry VEGFR1 Signaling Regulates IL-4-Mediated Arginase 1 Expression in Macrophages
Current Molecular Medicine “Something is Wrong in the Ras Kingdom” - Evidence for the Involvement of p21Ras/MAP Kinase in Autoimmune Diseases
Current Rheumatology Reviews